Parkinson's Disease KP Update

Similar documents
Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

Treatment of Parkinson s Disease: Present and Future

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

Optimizing Clinical Communication in Parkinson s Disease:

10th Medicine Review Course st July Prakash Kumar

WHAT DEFINES YOPD? HANDLING UNIQUE CONCERNS REBECCA GILBERT, MD, PHD VICE PRESIDENT, CHIEF SCIENTIFIC OFFICER, APDA MARCH 14, 2019

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

The Shaking Palsy of 1817

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Origins. Update on Parkinson s Disease

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Motor Fluctuations Stephen Grill, MD, PHD Parkinson s and Movement Disorders Center of Maryland and Johns Hopkins University

Movement Disorders: A Brief Overview

Advanced Therapies for Motor Symptoms in PD. Matthew Boyce MD

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

Objectives. Emerging Treatments in Parkinson s s Disease. Pathology. As Parkinson s progresses it eventually affects large portions of the brain.

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

PARKINSON S MEDICATION

Best Medical Treatments for Parkinson s disease

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

Parkinson s Disease Update

Moving fast or moving slow: an overview of Movement Disorders

Faculty. Joseph Friedman, MD

Parkinson s Disease Current Treatment Options

PD: Key Treatment Considerations

Surgical Management of Parkinson s Disease

Presented by Meagan Koepnick, Josh McDonald, Abby Narayan, Jared Szabo Mentored by Dr. Doorn

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Key Concepts and Issues in Parkinson s Disease in 2016

What is Parkinson s Disease?

05-Nov-15. Impact of Parkinson s Disease in Australia. The Nature of Parkinson s disease 21st Century

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

PD ExpertBriefings: Parkinson s Medications: Today and Tomorrow Led By: Cynthia L. Comella, M.D., F.A.A.N.

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Medication Management & Strategies When the levodopa honeymoon is over

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

Evaluation of Parkinson s Patients and Primary Care Providers

Clinical Features and Treatment of Parkinson s Disease

Prior Authorization with Quantity Limit Program Summary

Parkinson s Disease in the Elderly A Physicians perspective. Dr John Coyle

ASSFN Clinical Case: Bilateral STN DBS Implant for Parkinson s Disease

Evaluation and Management of Parkinson s Disease in the Older Patient

Welcome and Introductions

Welcome and Introductions

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

Safinamide: un farmaco innovativo con un duplice meccanismo d azione

Basal ganglia motor circuit

Margo J Nell Dept Pharmacology

Parkinson s Disease. Sirilak yimcharoen

Parkinson s disease. Information for patients and carers. The Leeds Teaching Hospitals NHS Trust

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

Drugs used in Parkinsonism

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Palladotomy and Pallidal Deep Brain Stimulation

Issues for Patient Discussion

Medications used to treat Parkinson s disease

Dr Barry Snow. Neurologist Auckland District Health Board

Parkinson s Disease. Gillian Sare

Anticholinergics. COMT* Inhibitors. Dopaminergic Agents. Dopamine Agonists. Combination Product

Part I Parkinson Disease Diagnosis and Treatment

Understanding Parkinson s Disease Important information for you and your loved ones

symptoms of Parkinson s disease EXCEPT.

Pa t h w a y s. Pa r k i n s o n s. MacMahon D.G. Thomas S. Fletcher P. Lee M. 2006

UNDERSTANDING PARKINSON S DISEASE

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

Indications. DBS for Tremor. What is the PSA? 6/08/2014. Tremor. 1. Tremor. 2. Gait freezing/postural instability. 3. Motor fluctuations

Parkinson Disease Treatment Research Pipeline Codrin Lungu MD Program Director, Office of Clinical Research Staff Clinician, Office of the Clinical

475 GERIATRIC PSYCHOPHARMACOLOGY (p.1)

Basal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota

10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.

A Four Point Plan for Enhanced Support for Parkinson s Disease In B.C.

Basal ganglia Sujata Sofat, class of 2009

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Let s Look at Parkinson s (PD) Sheena Morgan Parkinson s Disease Nurse Specialist Isle of Wight NHS Trust November 2016

Kinematic Modeling in Parkinson s Disease

What s new for diagnosing and treating Parkinson s Disease?

Appendix N: Research recommendations

Re-Submission. Scottish Medicines Consortium. rasagiline 1mg tablet (Azilect ) (No. 255/06) Lundbeck Ltd / Teva Pharmaceuticals Ltd.

Patient selection for surgery: Parkinson s disease

Continuous dopaminergic stimulation

Deep Brain Stimulation. Is It Right for You?

Ahead of the curve: Parkinson s Disease 101. Luisa Solis-Cohen, MD Movement Disorders Specialist Colorado Neurodiagnostics Littleton, CO

8/28/2017. Behind the Scenes of Parkinson s Disease

Parkinson s Disease Update. Colleen Peach, RN, MSN, FNP Movement Disorders Clinic Emory University School of Medicine March 7, 2015

III./3.1. Movement disorders with akinetic rigid symptoms

The motor regulator. 1) Basal ganglia/nucleus

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Communicating About OFF Episodes With Your Doctor

Parkinson s Disease in 60 minutes. Dr. Claire Hinnell Movement Disorder Neurologist Director Movement Disorder Clinic JPOCSC

Lecture XIII. Brain Diseases I - Parkinsonism! Brain Diseases I!

Transcription:

Parkinson's Disease KP Update Andrew Imbus, PA-C Neurology, Movement Disorders Kaiser Permanente, Los Angeles Medical Center No disclosures "I often say now I don't have any choice whether or not I have Parkinson's, but surrounding that non-choice is a million other choices that I can make." -Michael J. Fox Objectives Pathophysiology / Epidemiology Diagnosis and diagnostic challenges in PD Review the current medicinal and surgical treatments Offerings available at KP 1

Involuntary tremulous motion, with lessened muscular power, in parts not in action and even when supported; with a propensity to bend the trunk forward, and to pass from a walking to a running pace: the senses and intellects being uninjured. Parkinson s Disease Neurodegenerative disease, typically found later in life, linked to decreased dopamine production in the substantia nigra. Marked especially by tremor of resting muscles, rigidity, slowness of movement, impaired balance, and a shuffling gait. Epidemiology 1 2 million Americans 7 10 million worldwide Risks (incidence) 17.4 in 100,000 persons (age 50-59) 93.1 in 100,000 persons (age 70-79) Lancet 2009; 373: 2055 66 2

two regions of the country most involved in metal processing and agriculture.. Neuroepidemiology 2010;34:143 151 Antelope Valley San Bernandino Riverside Panorama City Downey Baldwin Park LAMC Woodland Hills Fontana Orange County San Diego LAMC PD Region So Cal Kaiser Permanente Statistics YTD Average Parkinson Patients Per Region 0 500 1000 1500 2000 2500 3000 3500 Introduction 3

Basal Ganglia Integrate and process information from cortex Provide feedback via the thalamus Works via direct and indirect pathways Alexander. Annu Rev Neurosci. 1986;9:357-81. Basal Ganglia Excitatory neurons Inhibitory neurons Desired actions Exp Brain Res. 2011 Apr;210(2):165-72. Basal Ganglia Front Neuroanat. 2011;5:39. 4

N Engl J Med 2008;359:2468-76. Pathology Motor signs and symptoms emerge with >60-80% loss of striatal dopamine Pathology 5

Pathology Evolution Neurology. 2009;72(Suppl 2):S21 S26 Pathology Mov Disord. 2012 Apr 15;27(5):608-16. Robin Williams 6

Associations with Parkinson s Protective factors? Associated factors Smoking Farming Coffee (caffeine) Teaching NSAIDs Healthcare work Exercise Well water Urban dwelling Family history Regular stools Risky behavior Increased uric acid Male Alcohol Introduction Decreased risk with alcohol consumption Mov Disord. 2014 May;29(6):819-22. Muhammad Ali Diagnosed in 1984 75 yo 7

Problems facing providers Uncertainty of diagnosis Patients can have 19 different specialists Unsure if PD symptoms or not What to expect next as course progresses How to improve quality of life in patients Not enough PD patient experiences Not asking the right questions Not getting the right answers Unclear of guidelines and red flags PD Diagnosis Motor Symptoms Tremor Rigidity Akinesia (bradykinesia) Postural Instability Mixed Symptoms Speech & swallowing difficulty Drooling Non-Motor Symptoms Hyposmia Mood changes Cognitive disorder Psychosis (visual / auditory) Orthostatic Hypotension RBD Bowel / Bladder disorders Sexual Disorders Weight control Impulse control Reasons for Diagnostic Uncertainty Mild intensity of signs Only one sign One sign with asymmetry Two signs but no bradykinesia Lack of progression over time Atypical signs Postural rather than rest tremor Mild rigidity Doubtful bradykinesia Little or no response to levodopa 8

Diagnostic Accuracy in PD Dopamine Transporter SPECT (DAT Scan) Distinguish Parkinsonism due to presynaptic dopaminergic loss from other causes Dopamine transporter imaging: May improve diagnostic accuracy in clinically uncertain syndromes May improve diagnostic confidence May have a strong influence on clinical management of patients May allow earlier diagnosis of patients with PS Improving Diagnostic Uncertainty Mov Disord. 2012 Apr 15;27(5):608-16. 9

Treatment Principles Primary Treatment anything that is established as Neuroprotective Exercise? Tailor treatment to the idea that this is a chronic disease Expect to change treatments as symptoms progress / change Keep patient functioning independently as long as possible Patients should be encouraged to remain physically active, mentally active, and take an active role in their care L-dopa equivalent dosage. MIRT, multidisciplinary intensive rehabilitation treatment. Patients in monotherapy with resagiline. MIRT, multidisciplinary intensive rehabilitation treatment. Neurorehabil Neural Repair 29, 123-131. 10

Parkinson Medication Treatments L-dopa derivatives Carbidopa Levodopa (CR) Rytary COMT Inhibitors Encapatone (Comtan) Dopamine Agonists Ropinirol (ER) // Pramipexole(ER) Rotigitone (Neurpo) patch MAO-Inhibitors Rasagaline (Azilect) Selegiline Safinimide (Xadago) Acteylglutamate Inhibitors Amantadine Motor Fluctuations 32 11

Duopa Pump (external pump with consistent levodopa infusion) Adenosine 30 years of follow-up of 8004 Japanese- American men Higher coffee and caffeine intake is associated with a significantly lower incidence of PD. Caffeine is a non-selective adenosine antagonist JAMA. 2000;283(20):2674-2679 Deep Brain Stimulation Only Deep 10-20% brain patients stimulation are candidates in advanced Parkinson s disease has Individualized appropriateness demonstrated More Improved dramatic motor improvement function with younger patients. Reduced OFF time Other Reduced uses being troublesome studied dyskinesias Tourette s Improved Syndrome quality of life Pain Reduced control reliance on meds (STN) 12

Micro-Electrode Recording (MER) ParkinsonNET An integrated multidisciplinary approach to the Parkinson's patient 13

And... why? So what you're trying to say is... 14

ParkinsonNet Approach Physical Therapy Occupational Therapy Speech Therapy Dietitian Social Worker Networking groups together ParkinsonNet Medical Team Medication adjustment Starting / stopping / adjusting Education Counseling Appropriate referrals Eval for next steps PDQ 39 questionnaire Collaborative decision making Los Angeles Kaiser 2 Neurology Movement Specialists 2 Neurology / Neurosurgery PAs 1 Neurosurgeon for DBS Regular rotation of NS residents 1 Nurse Case Manager 1 Neuropsychologist (testing) 1 Social worker Outside LAMC 6 Neurology Movement Specialists 15

16